Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10781695 | 0.77 | ALDH1A1 (0.41) | RYR2ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL10585357 | 0.75 | RYR2 (0.37) | RYR2ALDH1A1GAAMEN1NPC1 | |
| SCHEMBL8822493 | 0.75 | PLAU (0.45) | RYR2ALDH1A1GAAMEN1NPC1 | |
| SCHEMBL6446024 | 0.75 | RYR2 (0.34) | RYR2ALDH1A1MEN1NPC1KMT2A | |
| Hydrochloric Acid SCHEMBL10603702 | 0.73 | PLAU (0.44) | RYR2MEN1NPC1KMT2AIDO1 | |
| SCHEMBL7073263 | 0.72 | KMT2A (0.42) | RYR2MAPTTDP1GAAMEN1 | |
| SCHEMBL10346153 | 0.72 | RYR2 (0.35) | RYR2ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL315646 | 0.71 | IDO1 (0.46) | IDO1 | |
| SCHEMBL9214477 | 0.71 | ALDH1A1 (0.47) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL6447242 | 0.71 | RYR2 (0.34) | RYR2ALDH1A1HPGDGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0388528-B1 | Carboximidamide derivatives | KIRIN BREWERY (JP) | 1995-09-27 | — | — | EP | claimed |
| EP-0388528-A2 | Carboximidamide derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 1990-09-26 | — | — | EP | claimed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0388528-B1 | Carboximidamide derivatives | KIRIN BREWERY (JP) | 1995-09-27 | — | — | EP | disclosed |
| EP-0389425-B1 | Benzotiopyranyl amines | CIBA GEIGY AG (CH) | 1995-04-26 | — | — | EP | disclosed |
| US-5223508-A | Hypotensive agents, vasodilators | KIRIN BEER KABUSHIKI KAISHA (JP) | 1993-06-29 | — | — | US | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| US-5166347-A | Hypotensive agents, cardiovascular disorders, antiischemic agents and anticoagulants | KIRIN BEER KABUSHIKI KAISHA (JP) | 1992-11-24 | — | — | US | disclosed |
| US-5071858-A | Antipsychotic benzothiopyranylamines | CIBA-GEIGY CORPORATION (US) | 1991-12-10 | — | — | US | disclosed |
| US-5071858-A | Antipsychotic benzothiopyranylamines | CIBA-GEIGY CORPORATION (US) | 1991-12-10 | — | — | US | disclosed |
| EP-0388528-A2 | Carboximidamide derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0389425-A1 | Benzotiopyranyl amines | CIBA-GEIGY AG (CH) | 1990-09-26 | — | — | EP | disclosed |
| EP-0389425-A1 | Benzotiopyranyl amines | CIBA-GEIGY AG (CH) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | RYR2 1026/4885ALDH1A1 889/4885MAPT 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.